The TH3RESA study: TDM-1 doubles progression free survival in HER-2 positive refractory metastatic breast cancer.
AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to conventional therapies in the phase three TH3RESA study presented to the 2013 European Cancer …